Is Abbott’s Spinoff the Beginning of a Trend?

A look at Abbott Labs' (ABT) breakup indicates splitting up may be good medicine for other diversified health care companies.

Pfizer Crafting a Post-Patent Game Plan

As its Lipitor patent nears expiration, Pfizer considers new uses for Lyrica, its popular painkiller for fibromyalgia.

FDA Process, Taxes Spurring Exodus of Medical Device Firms

Tax incentives for R&D, quicker FDA approvals needed to stem exodus of U.S. medical device firms, industry studies show.

Heed the Red Flags at Amedisys

Congressional scrutiny of home health care specialist Amedisys, along with lowered guidance, are sure-fire signs that investors should proceed with care.

Lilly Should Survive Patent Loss on Blockbuster Drug Zyprexa

On Oct. 23, Eli Lilly will wave goodbye to the U.S. patent on the best-selling drug in its 135-year history. Here's why investors shouldn't be worried.

Onyx’s Staying Power Tied to New Cancer Drug Carfilzomib

Onyx needs the financial boost from its multiple myeloma-treating drug to ween it off dependence on an uneasy partnership with Bayer.

Suit Asks J&J CEO to Return Part of 2010 Pay

J&J CEO Bill Weldon’s gains don’t reflect shareholder pain, some stakeholders say.

Study Results Boost Analyst’s Forecast for Novartis Drug

An analyst boosts his forecast for Novartis' Afinitor based on its promise as a treatment for breast cancer.

FDA’s Easing on Obesity Drugs Could Fatten Investor Wallets

Vivus and Orexigen's diet-pill hopes are resurrected as the FDA relaxes its stance against obesity treatments.

Shortage of Cancer Drugs Jeopardizes Development of New Treatments

Existing products often are used in new drugs' clinical trials, meaning a cramp in supply can result in delays of even years for new treatments.

Express Scripts-Medco Merger Still Looks Like a Go

Consumer groups and Big Pharma don’t like it, but the FTC still is likely to OK the Medco-Express Scripts merger.

New CEO Tasked with Getting Hospira Back on Track

Priorities for Hospira's new CEO include fixing manufacturing problems, launching biosimilars in the U.S.

Fair or Not, Patent Overhaul Bill Looks Like a Win for Big Pharma

'First-inventor-to-file' system is a victory for Big Pharma and its investors, but a crushing blow to small companies.

Glaxo Alters R&D Process to Ensure Survival in Changing Pharma Industry

GSK has created a "dragon" culture in its R&D process. Here's what it is and why analysts like the Glaxo approach.

AstraZeneca Rolls the Dice on Cholesterol Drug and Comes Up Short

Once the patent for Pfizer's popular Lipitor runs out, cheap knockoffs could start eating away at Crestor sales

Johnson & Johnson a Safe Play for Income

JNJ's financials are solid, and the company is making strides toward getting 11 new drugs approved by the end of 2015.

In Event of Bird Flu Pandemic, Vaccine Producers Likeliest to Prosper

A mutant strain of H5N1 could be spreading in Asia, meaning vaccine heavyweights might be going back to the drawing board.

Insider Bets Big That Seattle Genetics Cancer Drug Can Buck Dendreon Effect

Similar drugs in Adcetris' high price range also faring well, which is cause for optimism, but SGEN's lack of other drugs near the end of the pipeline should make investors wary.

Share Prices of Bristol-Myers, Pfizer Could Jump on Positive Blood-Thinner Study Data

Rush to replace warfarin is a big opportunity for the drug industry, and this pair of pharmaceuticals could use the help.

More Tightly Focused Biogen Appears to Have Greater Upside

With many of its drugs in Phase III clinical trials, including a promising treatment for MS, Biogen has upside potential.